bosutinib (BioDeep_00000858505)
代谢物信息卡片
Bosutinib (SKI-606)
化学式: C26H29Cl2N5O3 (529.1647344)
中文名称: 伯舒替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
InChI: InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:39112
- KEGGdrug: D03252
- PubChem: 5328940
- DrugBank: DB06616
- ChEMBL: CHEMBL288441
- CAS: 380843-75-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Tensei Hirasawa, Masafumi Kikuchi, Kensuke Shigeta, Shinya Takasaki, Yu Sato, Toshihiro Sato, Jiro Ogura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Masamitsu Maekawa, Nariyasu Mano. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Biomedical chromatography : BMC.
2021 Aug; 35(8):e5124. doi:
10.1002/bmc.5124. [PMID: 33772839] - Yuji Mukai, Yuka Yoshida, Tatsunari Yoshida, Takeshi Kondo, Nobuo Inotsume, Takaki Toda. Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis.
Therapeutic drug monitoring.
2021 06; 43(3):386-393. doi:
10.1097/ftd.0000000000000825. [PMID: 33065614] - Derek J B Kleinveld, Liza Botros, M Adrie W Maas, Jesper Kers, Jurjan Aman, Markus W Hollmann, Nicole P Juffermans. Bosutinib reduces endothelial permeability and organ failure in a rat polytrauma transfusion model.
British journal of anaesthesia.
2021 May; 126(5):958-966. doi:
10.1016/j.bja.2021.01.032. [PMID: 33685634] - Illias Tazi. [Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Bulletin du cancer.
2021 Apr; 108(4):435-437. doi:
10.1016/j.bulcan.2020.12.009. [PMID: 33663776] - Maiko Abumiya, Naoto Takahashi, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Masatomo Miura. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.
Scientific reports.
2021 03; 11(1):6362. doi:
10.1038/s41598-021-85757-7. [PMID: 33737618] - Kana Koinuma, Toru Sakairi, Yoshikazu Watanabe, Azusa IIzuka, Mitsuharu Watanabe, Hiroko Hamatani, Masao Nakasatomi, Takuma Ishizaki, Hidekazu Ikeuchi, Yoriaki Kaneko, Keiju Hiromura. A case of long-term dasatinib-induced proteinuria and glomerular injury.
CEN case reports.
2020 11; 9(4):359-364. doi:
10.1007/s13730-020-00484-8. [PMID: 32388829] - Yasuhiro Taniguchi, Naoto Takahashi, Masatomo Miura, Chikara Hirase, Sanae Sueda, Jorge Luis Espinoza, Shinya Rai, Shoko Nakayama, Kentaro Serizawa, Takahiro Kumode, Yosaku Watatani, Yasuyoshi Morita, Hirokazu Tanaka, Itaru Matsumura. The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia.
Internal medicine (Tokyo, Japan).
2020 Nov; 59(21):2745-2749. doi:
10.2169/internalmedicine.4871-20. [PMID: 32641651] - Jeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan. Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect.
Pharmaceutical research.
2020 Jun; 37(7):128. doi:
10.1007/s11095-020-02834-8. [PMID: 32529309] - Tim Wenzel, Thomas Büch, Nicole Urban, Ulrike Weirauch, Katrin Schierle, Achim Aigner, Michael Schaefer, Hermann Kalwa. Restoration of MARCKS enhances chemosensitivity in cancer.
Journal of cancer research and clinical oncology.
2020 04; 146(4):843-858. doi:
10.1007/s00432-020-03149-2. [PMID: 32056006] - Yuji Mukai, Tatsunari Yoshida, Takeshi Kondo, Nobuo Inotsume, Takaki Toda. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2020 Jan; 1137(?):121928. doi:
10.1016/j.jchromb.2019.121928. [PMID: 31877431] - Lei Ye, Jingjing Chen, Shuang-Long Li, Yong-Liang Zhu, Saili Xie, Xiaoxiang Du. UPLC-MS/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2020 Jan; 177(?):112850. doi:
10.1016/j.jpba.2019.112850. [PMID: 31499430] - Jingjing Chen, Yuanyuan Shao, Huidan Zhu, Xiufang Chen, Xuemei Ye. Liquid chromatography-tandem mass spectrometric method for the quantification of eliglustat in rat plasma and the application in a pre-clinical study.
Journal of pharmaceutical and biomedical analysis.
2020 Jan; 177(?):112858. doi:
10.1016/j.jpba.2019.112858. [PMID: 31518862] - Masatomo Miura, Naoto Takahashi. [Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2019; 60(9):1140-1147. doi:
10.11406/rinketsu.60.1140. [PMID: 31597837] - Shinji Yamazaki, Cho-Ming Loi, Emi Kimoto, Chester Costales, Manthena V Varma. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Drug metabolism and disposition: the biological fate of chemicals.
2018 Aug; 46(8):1200-1211. doi:
10.1124/dmd.118.080424. [PMID: 29739809] - Maiko Abumiya, Akiko Mita, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi, Masatomo Miura. Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Medical oncology (Northwood, London, England).
2018 May; 35(6):90. doi:
10.1007/s12032-018-1146-z. [PMID: 29736778] - Poe-Hirr Hsyu, Daniela Soriano Pignataro, Kyle Matschke. Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.
Clinical pharmacology in drug development.
2018 05; 7(4):373-381. doi:
10.1002/cpdd.396. [PMID: 29058816] - Takahiro Sumimoto, Ryosuke Nakahara, Yuhki Sato, Hiroki Itoh. A quantitative method for the determination of bosutinib in human plasma using high-performance liquid chromatography and ultraviolet detection.
Journal of clinical laboratory analysis.
2018 Jan; 32(1):. doi:
10.1002/jcla.22201. [PMID: 28374910] - Suma K Pawar, Roopa S Naik, J Seetharamappa. Exploring the binding of two potent anticancer drugs bosutinib and imatinib mesylate with bovine serum albumin: spectroscopic and molecular dynamic simulation studies.
Analytical and bioanalytical chemistry.
2017 Nov; 409(27):6325-6335. doi:
10.1007/s00216-017-0565-6. [PMID: 28852787] - Vladimir Tesar, Kazimierz Ciechanowski, York Pei, Irina Barash, Megan Shannon, Ray Li, Jason H Williams, Matteo Levisetti, Steven Arkin, Andreas Serra. Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.
Journal of the American Society of Nephrology : JASN.
2017 Nov; 28(11):3404-3413. doi:
10.1681/asn.2016111232. [PMID: 28838955] - Hiroshi Nishi, Kazuhiro Furuhashi, Xavier Cullere, Gurpanna Saggu, Mark J Miller, Yunfeng Chen, Florencia Rosetti, Samantha L Hamilton, Lihua Yang, Spencer P Pittman, Jiexi Liao, Jan M Herter, Jeffrey C Berry, Daniel J DeAngelo, Cheng Zhu, George C Tsokos, Tanya N Mayadas. Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.
The Journal of clinical investigation.
2017 Oct; 127(10):3810-3826. doi:
10.1172/jci94039. [PMID: 28891817] - Jorge E Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, Hagop M Kantarjian, Jeff H Lipton, Amit Lahoti, Moshe Talpaz, Ewa Matczak, Elly Barry, Eric Leip, Tim H Brümmendorf, H Jean Khoury. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
Clinical lymphoma, myeloma & leukemia.
2017 10; 17(10):684-695.e6. doi:
10.1016/j.clml.2017.06.001. [PMID: 28807791] - Hanna L M Rajala, Mohamed El Missiry, Anniina Ruusila, Perttu Koskenvesa, Tim H Brümmendorf, Bjorn T Gjertsen, Jeroen Janssen, Kourosh Lotfi, Berit Markevärn, Ulla Olsson-Strömberg, Leif Stenke, Jesper Stentoft, Johan Richter, Henrik Hjorth-Hansen, Anna Kreutzman, Satu Mustjoki. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
Journal of cancer research and clinical oncology.
2017 Aug; 143(8):1543-1554. doi:
10.1007/s00432-017-2378-6. [PMID: 28337541] - Hongyan Dong, Michael G Wade. Application of a nonradioactive assay for high throughput screening for inhibition of thyroid hormone uptake via the transmembrane transporter MCT8.
Toxicology in vitro : an international journal published in association with BIBRA.
2017 Apr; 40(?):234-242. doi:
10.1016/j.tiv.2017.01.014. [PMID: 28119167] - Poe-Hirr Hsyu, Daniela Soriano Pignataro, Kyle Matschke. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
European journal of clinical pharmacology.
2017 Jan; 73(1):49-56. doi:
10.1007/s00228-016-2108-z. [PMID: 27718000] - Poe-Hirr Hsyu, Daniela Soriano Pignataro, Kyle Matschke. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.
European journal of clinical pharmacology.
2017 Jan; 73(1):57-63. doi:
10.1007/s00228-016-2115-0. [PMID: 27717999] - Richat Abbas, Poe-Hirr Hsyu. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.
Clinical pharmacokinetics.
2016 10; 55(10):1191-1204. doi:
10.1007/s40262-016-0391-6. [PMID: 27113346] - Yihua Xu, Xin-ce Huang, Shengjie Dai, Yuwu Xiao, Meng-tao Zhou. A simple method for the determination of Bosutinib in rat plasma by UPLC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 Nov; 1004(?):93-7. doi:
10.1016/j.jchromb.2015.09.030. [PMID: 26454795] - Harshani R Lawrence, Kiran Mahajan, Yunting Luo, Daniel Zhang, Nathan Tindall, Miles Huseyin, Harsukh Gevariya, Sakib Kazi, Sevil Ozcan, Nupam P Mahajan, Nicholas J Lawrence. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
Journal of medicinal chemistry.
2015 Mar; 58(6):2746-63. doi:
10.1021/jm501929n. [PMID: 25699576] - Richat Abbas, Joseph Boni, Daryl Sonnichsen. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
Drug metabolism and personalized therapy.
2015 Mar; 30(1):57-63. doi:
10.1515/dmdi-2014-0026. [PMID: 25803093] - Chen Wenqiang, Irina Lonskaya, Michaeline L Hebron, Zainab Ibrahim, Rafal T Olszewski, Joseph H Neale, Charbel E-H Moussa. Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice.
Human molecular genetics.
2014 Sep; 23(18):4960-9. doi:
10.1093/hmg/ddu211. [PMID: 24847002] - Kendra H Oliver, Tammy Jessen, Emily L Crawford, Chang Y Chung, James S Sutcliffe, Ana M Carneiro. Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.
Molecular pharmacology.
2014 Jun; 85(6):921-31. doi:
10.1124/mol.114.091736. [PMID: 24695082] - Doreen Braun, Ulrich Schweizer. Authentic bosutinib inhibits triiodothyronine transport by monocarboxylate transporter 8.
Thyroid : official journal of the American Thyroid Association.
2014 May; 24(5):926-7. doi:
10.1089/thy.2013.0660. [PMID: 24479416] - Richat Abbas, Cathie Leister, Daryl Sonnichsen. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
Clinical drug investigation.
2013 Aug; 33(8):589-95. doi:
10.1007/s40261-013-0103-z. [PMID: 23839484] - Richat Abbas, Stephan Chalon, Cathie Leister, Myriam El Gaaloul, Daryl Sonnichsen. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
Cancer chemotherapy and pharmacology.
2013 Jan; 71(1):123-32. doi:
10.1007/s00280-012-1987-7. [PMID: 23053269] - Richat Abbas, Cathie Leister, Myriam El Gaaloul, Stephan Chalon, Daryl Sonnichsen. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Clinical therapeutics.
2012 Sep; 34(9):2011-9.e1. doi:
10.1016/j.clinthera.2012.07.006. [PMID: 22884766] - Marek Dziadosz, Rüdiger Lessig, Heidemarie Bartels. HPLC-DAD protein kinase inhibitor analysis in human serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Apr; 893-894(?):77-81. doi:
10.1016/j.jchromb.2012.02.037. [PMID: 22425385] - Richat Abbas, Bruce A Hug, Cathie Leister, Myriam El Gaaloul, Stephan Chalon, Daryl Sonnichsen. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Cancer chemotherapy and pharmacology.
2012 Jan; 69(1):221-7. doi:
10.1007/s00280-011-1688-7. [PMID: 21691746] - Ming-Yang Chang, Albert C M Ong. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.
Nephron. Clinical practice.
2012; 120(1):c25-34; discussion c35. doi:
10.1159/000334166. [PMID: 22205396] - Weng Ieong Tou, Calvin Yu-Chian Chen. In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
PloS one.
2012; 7(3):e33728. doi:
10.1371/journal.pone.0033728. [PMID: 22470466] - Doreen Braun, Theo D Kim, Philipp le Coutre, Josef Köhrle, Jerome M Hershman, Ulrich Schweizer. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.
The Journal of clinical endocrinology and metabolism.
2012 Jan; 97(1):E100-5. doi:
10.1210/jc.2011-1837. [PMID: 22031512] - Richard J Aspinall, Sara M Weis, Leo Barnes, Kimberly Lutu-Fuga, David J Bylund, Paul J Pockros, David A Cheresh. A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.
Liver international : official journal of the International Association for the Study of the Liver.
2011 Sep; 31(8):1222-30. doi:
10.1111/j.1478-3231.2011.02554.x. [PMID: 21745297] - Justine Elliott, Nadezhda N Zheleznova, Patricia D Wilson. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation.
American journal of physiology. Cell physiology.
2011 Aug; 301(2):C522-9. doi:
10.1152/ajpcell.00163.2010. [PMID: 21508333] - Nesly Dotan, Solomon P Wasser, Jamal Mahajna. The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator.
Integrative cancer therapies.
2011 Jun; 10(2):148-59. doi:
10.1177/1534735410383169. [PMID: 21147815] - Eric A Murphy, Bharat K Majeti, Rajesh Mukthavaram, Lisette M Acevedo, Leo A Barnes, David A Cheresh. Targeted nanogels: a versatile platform for drug delivery to tumors.
Molecular cancer therapeutics.
2011 Jun; 10(6):972-82. doi:
10.1158/1535-7163.mct-10-0729. [PMID: 21518727] - Asish K Ghosh, Charla Secreto, Justin Boysen, Traci Sassoon, Tait D Shanafelt, Debabrata Mukhopadhyay, Neil E Kay. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
Blood.
2011 Feb; 117(6):1928-37. doi:
10.1182/blood-2010-09-305649. [PMID: 21135257] - William E Sweeney, Rodo O von Vigier, Philip Frost, Ellis D Avner. Src inhibition ameliorates polycystic kidney disease.
Journal of the American Society of Nephrology : JASN.
2008 Jul; 19(7):1331-41. doi:
10.1681/asn.2007060665. [PMID: 18385429] - Dan M Berger, Minu Dutia, Gary Birnberg, Dennis Powell, Diane H Boschelli, Yanong D Wang, Malini Ravi, Deanna Yaczko, Jennifer Golas, Judy Lucas, Frank Boschelli. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
Journal of medicinal chemistry.
2005 Sep; 48(19):5909-20. doi:
10.1021/jm050512u. [PMID: 16161995] - Jennifer M Golas, Judy Lucas, Carlo Etienne, Jonathan Golas, Carolyn Discafani, Latha Sridharan, Erwin Boghaert, Kim Arndt, Fei Ye, Diane H Boschelli, Fangbiao Li, Craig Titsch, Christine Huselton, Inder Chaudhary, Frank Boschelli. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Cancer research.
2005 Jun; 65(12):5358-64. doi:
10.1158/0008-5472.can-04-2484. [PMID: 15958584] - D H Boschelli, F Ye, Y D Wang, M Dutia, S L Johnson, B Wu, K Miller, D W Powell, D Yaczko, M Young, M Tischler, K Arndt, C Discafani, C Etienne, J Gibbons, J Grod, J Lucas, J M Weber, F Boschelli. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.
Journal of medicinal chemistry.
2001 Nov; 44(23):3965-77. doi:
10.1021/jm0102250. [PMID: 11689083]